Mark Terry, MD
Cornea and External Diseases Specialist · Portland, ORNPI 1760498737
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $81,252 of the $104,124 with a category attached, or 78.0%. 9 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 44.2% of the total.
Across 43 payments — averaging $2421.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$46K
- Bausch & Lomb Americas Inc.$45K
- Moria Inc$10K
- Eyevance Pharmaceuticals LLC$1K
- W. L. Gore & Associates, Inc.$1K
- Alcon$124
- plus $261 from 3 others
What the payments were for
- Royalty or licence$81,25278%
- Consulting fees$2,4502%
- Speaking & faculty fees$5,0005%
- Grants$15,00014%
- Food & beverage$4220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $46,071 |
| Bausch & Lomb Americas Inc. | 16 | $45,182 |
| Moria Inc | 2 | $10,000 |
| Eyevance Pharmaceuticals LLC | 2 | $1,287 |
| W. L. Gore & Associates, Inc. | 2 | $1,200 |
| Alcon | 1 | $124 |
| Oyster Point Pharma, Inc. | 1 | $94 |
| Biotissue Holdings Inc. | 2 | $90 |
| Glaukos Corporation | 3 | $77 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPHTHALMIC INSTRUMENTS$81,252
- Flarex$1,250
- Product in Development$1,200
- Clareon$124
How this compares
Too few cornea and external diseases specialist providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 431 | $20,140 |
| Fluorometholone | 181 | $17,360 |
| Lotemax SmLoteprednol Etabonate | 13 | $3,242 |
| Doxycycline Monohydrate | 33 | $2,271 |
| Loteprednol Etabonate | 18 | $2,208 |
| ValacyclovirValacyclovir Hcl | 49 | $1,903 |
| Acyclovir | 54 | $1,673 |
| Ofloxacin | 108 | $1,243 |
| Doxycycline Hyclate | 33 | $698 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 31 | $539 |
| Timolol Maleate | 18 | $152 |
| ErythromycinErythromycin Base | 20 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $46,071 | $5,45031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Portland
- Winston ChamberlainPortland$27K
- Michael StraikoPortland$15K
- John ClementsPortland$3K
- David DemillPortland$1K
- Roma PeganyPortland$724
- Afshan NanjiPortland$410
- Ashlin JoyePortland$368
- Matthew OlivaMedford$949
- John WellingMedford$757
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.